On the basis of these findings, we propose that BMP4 and BMP receptor antagonists such as DMH2 [35] can be applied to establish prognostic markers or identify therapeutic targets in patients with lung adenocarcinoma. The gene discussed is BMP4; the disease is lung adenocarcinoma.